Navigation Links
Mesa Labs Reports Higher First Quarter Earnings

LAKEWOOD, Colo., Aug. 11 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: MLAB) today reported higher earnings for the fiscal first quarter ended June 30, 2009.


  • First quarter revenues decreased less than 2% from last fiscal year
  • Operating income increased 5% over last fiscal year
  • Medical Product sales increase 12%
  • Raven Biological Indicator Product sales increase 16%

For the first quarter of fiscal 2010, net sales decreased two percent to $4,977,000 from $5,054,000 in the same quarter last year. Net income for the quarter increased one percent to $1,026,000 or $.31 per diluted share of common stock compared to $1,016,000 or $.31 per diluted share of common stock last year.

"During a time when many other companies are really struggling, we are pleased to report increased profits compared to last year," said John J. Sullivan, President and Chief Executive Officer. "This first quarter of our new fiscal year started off well and, while revenue decreased slightly compared to last year, we actually posted five percent higher orders during the quarter than the comparable period last year. Both orders and sales for our Medical and Raven lines continue to grow well, while the DataTrace line is still struggling. However, after seeing large sequential quarter-to-quarter decreases in DataTrace orders, we have recently seen a stabilization of this business, albeit at a lower level than this time last year. We are hopeful for a recovery in the DataTrace business going forward, as our customer's focus on increasing their capital equipment spending. We are also pleased with our profits this quarter. As always, we continue to closely monitor our expenses and take appropriate action to optimize the company's profit performance. While we are happy to report a five percent increase in operating profit, it did not result in a concomitant increase in net income due partially to a 79 percent decrease in the interest income on cash investments. Unless we see further weakening in the economy, in the months ahead we expect to build on the momentum established in the Medical and Raven businesses, while getting DataTrace back on a growth track."

During the first quarter of fiscal 2010, sales of the Company's medical products and services increased 12 percent compared to the prior year period. This increase was due to higher sales of dialysis meters, calibration solutions and dialysis meter service.

During the first quarter of fiscal 2010, DataTrace sales decreased 26 percent compared to the same period last year. The decrease in DataTrace sales during the quarter is the result of lower shipments of our Micropack III products and accessories, which were only partially off-set by sales of our new Micropack RF products.

Raven sales for the first quarter increased 16 percent compared to the first quarter of the prior year. The Raven biological indicator products saw sales gains in its core biological indicator strip business. Sales of Prospore and Protest products continue to increase, and we have expanded our manufacturing capacity for these products during the past fiscal year to allow the company to pursue additional opportunities for growth of these products. We also saw a substantial increase in sales of our chemical indicator products during the first quarter.

Profitability for fiscal 2010 increased slightly compared to the prior fiscal year. Gross margins decreased due to lower sales of higher margin DataTrace products and higher sales of lower margin Raven Biological Indicator products. This decrease in gross profits was off-set by reductions in operating expenses during the quarter.

Mesa Laboratories develops, acquires, manufactures and markets electronic instruments and disposables for industrial, pharmaceutical and medical applications.

This news release contains forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those in any such forward-looking statements. Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company's Annual Report on Form 10-K for the year ended March 31, 2009 as filed with the Securities and Exchange Commission, and from time to time in the Company's other reports on file with the Commission.

                                FINANCIAL SUMMARY

                                                 Quarter Ended June 30
                                                 2009              2008
                                                 ----              ----
    Net Sales                                $4,977,000        $5,054,000
    Cost of Goods                             1,994,000         1,850,000
                                            -----------       -----------
    Gross Profit                              2,983,000         3,204,000
    Operating Expense                         1,375,000         1,668,000
                                            -----------       -----------
    Operating Income                          1,608,000         1,536,000
    Other (Income) & Expense                     (6,000)          (29,000)
                                            -----------       -----------
    Earnings Before Taxes                     1,614,000         1,565,000
    Income Taxes                                588,000           549,000
                                            -----------       -----------
    Net Income                               $1,026,000        $1,016,000
                                            ===========       ===========

    Earnings Per Share (Basic)               $      .32        $      .32
                                            ===========       ===========
    Earnings Per Share (Diluted)             $      .31        $      .31
                                            ===========       ===========

    Average Shares (Basic)                    3,187,000         3,170,000
                                            ===========       ===========
    Average Shares (Diluted)                  3,258,000         3,264,000
                                            ===========       ===========

    BALANCE SHEETS (Unaudited)
                                               June 30          March 31
                                                2009              2009
                                                ----              ----
    Cash and Short-Term Investments         $10,759,000        $9,111,000
    Other Current Assets                      8,719,000         9,482,000
                                            -----------       -----------
    Total Current Assets                     19,478,000        18,593,000
    Property and Equipment                    3,826,000         3,879,000
    Other Assets                              7,039,000         7,142,000
                                            -----------       -----------
    Total Assets                            $30,343,000       $29,614,000
                                            ===========       ===========

                                            -----------       -----------
    Liabilities                             $ 2,001,000       $ 2,012,000
    Stockholders' Equity                     28,342,000        27,602,000
                                            -----------       -----------

    Total Liabilities and Equity            $30,343,000       $29,614,000
                                            ===========       ===========

SOURCE Mesa Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Physician Owned and Operated Hospitals Get Top Rankings From Consumer Reports, but They Remain on the Healthcare Reform Chopping Block
2. Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments
3. Winner Medical Reports Third Quarter Fiscal 2009 Results
4. Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
5. DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results
6. Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results
7. Cardiac Science Reports Q2 Revenue; Resumes AED Shipments
8. PAREXEL International Reports Fourth Quarter and Fiscal Year 2009 Results
9. Milestone Scientific Reports 44% Increase in Revenues in First Six Months of 2009 Compared to Prior Year
10. Pharmasset Reports Fiscal Third Quarter 2009 Financial Results
11. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology: